ERBB2 and cancer: To demonstrate that working with a radiolabel is not a necessity for estimating target number through depletion modelling, the two HER2 targeting antibodies Trastuzumab and Pertuzumab were fluorescently labelled and their binding to the HER2-overexpressing cancer cell line SKOV3 was recorded with LigandTracer Green.